论文部分内容阅读
目的:探讨应用肺表面活性物质(PS)联合NCPAP预防与治疗早产儿呼吸窘迫综合征(RDS)的近期预后。方法:40例胎龄<34周、出生体重<2 000 g的早产儿分为预防组和治疗组各20例,预防组为应用PS治疗前未出现呼吸窘迫症状、胸片无RDS改变,治疗组为治疗前出现呼吸窘迫症状、胸片提示有不同程度RDS改变,两组均联合应用NCPAP。结果:预防组NCPAP使用时间、用氧时间显著少于治疗组,差异有统计学意义(P<0.05),住院时间平均缩短5天(P>0.05),而并发症的发生、生后6个月内呼吸道疾病的发生频率、因呼吸道疾病再住院的频率及矫正年龄6个月的智测差异无统计学意义(P>0.05)。结论:生后早期应用肺表面活性物质联合NCPAP可以减少NCPAP使用时间、用氧时间、住院时间,对并发症的发生、生后早期呼吸道疾病的发生频率、因呼吸道疾病再住院的频率及智力发育无显著影响。
Objective: To investigate the short-term prognosis of respiratory distress syndrome (RDS) in the prevention and treatment of premature infants by using pulmonary surfactant (PS) combined with NCPAP. Methods: Forty preterm infants with gestational age <34 weeks and birth weight <2,000 g were divided into prevention group and treatment group with 20 cases each. The prevention group had no respiratory distress symptoms before PS treatment and no change of RDS in chest X - ray. Group before treatment appeared respiratory distress symptoms, chest X-ray showed varying degrees of change in both groups were combined with NCPAP. Results: The time of using NCPAP in prevention group was significantly shorter than that in treatment group (P <0.05), and the length of stay in hospital was shortened by 5 days (P> 0.05), while the incidence of complications was 6 There was no significant difference in the frequency of respiratory diseases, the frequency of hospitalization due to respiratory diseases and the 6 months of correctional age (P> 0.05). CONCLUSIONS: Early application of pulmonary surfactant in combination with NCPAP can reduce NCPAP use time, oxygen time, hospital stay, incidence of complications, incidence of early post-natal respiratory disease, frequency of rehospitalization due to respiratory disease, and mental development No significant effect.